Market News & Trends
SGS Enrolls First Patient Into Biophytis COVA Clinical Study, a COVID-19 Related Acute Respiratory Failure Treatment Clinical Trial
SGS recently announce the enrollment of the first patient into an important new clinical trial designed to examine the safety, tolerability, and efficacy of….
Gilead Sciences & Jounce Therapeutics Announce Exclusive License Agreement
Gilead Sciences, Inc. recently announced an agreement with Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, to exclusively…
Avomeen & Daré Bioscience Form Strategic Partnership to Accelerate Novel Pipeline
Avomeen and Daré Bioscience, Inc. recently announced the companies have signed an agreement under which Avomeen will provide….
Alimera Sciences Announces Enrollment of First Patient in Landmark NEW DAY Clinical Trial
Alimera Sciences, Inc. recently announced it has enrolled the first patient in the company’s NEW DAY clinical trial, a randomized, controlled, multi-center study designed to…
Chiasma Announces US Commercial Launch & Availability of the First & Only Oral Somatostatin Analog
Chiasma, Inc. recently announced the commercial launch and availability of MYCAPSSA (octreotide) capsules in the US for patients with acromegaly. MYCAPSSA, the first and only….
CorMedix Announces FDA Acceptance for Filing & Priority Review of NDA
CorMedix Inc. recently announced the US FDA has accepted for filing the company’s submitted New Drug Application (NDA) for Defencath, its product candidate to be…
LSNE-León Receives Approval From AEMPS to Manufacture Biotechnology-Based Therapeutic Products
LSNE Contract Manufacturing recently announced that the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved the manufacturing of clinical-stage biotechnology-based therapeutic products at…
Novavax & Canada Reach Agreement in Principle to Acquire COVID-19 Vaccine
Novavax, Inc. recently announced it has reached an agreement in principle with the Government of Canada to supply up to 76 million doses of NVX-CoV2373,…
First Patient Dosed in AstraZeneca’s Phase 3 COVID-19 Vaccine Trial
Headlands Research is pleased to announce that on Friday, Aug. 28, its JEM Research Institute clinical trial site in Lake Worth, FL, successfully dosed the…
Catalent Biologics Invests $50 Million to Add Third High-Speed Vial Line
Catalent recently announced it is investing $50 million to install an additional high-speed vial filling line at its Bloomington, IN, facility. The new line is…
Micron Biomedical Progresses With Clinical Evaluation of its Technology for Measles-Rubella Vaccination
Micron Biomedical, Inc. (Micron) recently received a second tranche of funding ($2.6 million) to continue clinical development of its microneedle-based technology for measles and rubella…
Rain Therapeutics Announces License Agreement for the Development of Proprietary RAD52 Inhibitors
Rain Therapeutics Inc. recently announced the signing of an exclusive, worldwide license agreement of a Drexel University research program to Rain for small molecule inhibitors of….
Cancer Genetics & StemoniX Sign Definitive Agreement to Merge
Cancer Genetics, Inc. and StemoniX, Inc. recently announced the entry into a definitive merger agreement. Cancer Genetics is a leader in drug discovery and….
Catalent Signs Agreement With AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine
Catalent, Inc. recently announced that Catalent Cell & Gene Therapy will provide drug substance manufacturing to AstraZeneca for the University of Oxford’s adenovirus vector-based COVID-19 vaccine….
Trishula Therapeutics Established to Advance Novel TTX-030, an Anti-CD39 Antibody
Recently, Trishula Therapeutics was launched to be solely dedicated to the development of TTX-030, a first-in-class anti-CD39 antibody, being studied in advanced cancers. The new…
Independent Studies Confirm Low Levels of Immune System Protein, Gelsolin, Associated With COVID-19 Severity
BioAegis Therapeutics Inc. recently announced that recent publications of independent studies have reported that low levels of gelsolin are associated with severe illness and organ…
Onconova Therapeutics Announces Topline Results From Pivotal Phase 3 INSPIRE Trial
Onconova Therapeutics, Inc. recently announced that INSPIRE, the company’s pivotal Phase 3 study assessing the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS)…
EDAP Announces Approval for Phase 2 Study
EDAP TMS SA recently announced it has received approval from French health authorities to initiate a Phase 2 multicenter clinical trial evaluating its Focal One…
BioAge Discovers Key Pathway & Identifies Promising Phase 2-Ready Drug to Treat & Reverse Immune Aging, a Root Cause of COVID-19 Morbidity & Mortality in Older Patients
BioAge Labs, Inc. recently announced it has in-licensed a clinical-stage therapy with significant promise and potential in treating immune aging in older patients hospitalized with…
AbbVie Submits Regulatory Application to FDA for RINVOQ
AbbVie recently announced it has submitted an application for a new indication to the US FDA for RINVOQ (upadacitinib; 15 mg, once daily), a selective…
